Insider Selling: Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells 2,500 Shares of Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $7.82, for a total value of $19,550.00. Following the completion of the sale, the chief executive officer now owns 120,695 shares of the company’s stock, valued at approximately $943,834.90. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Richard Nolan Townsend also recently made the following trade(s):

• On Thursday, October 10th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $8.10, for a total value of $40,500.00.
• On Tuesday, September 10th, Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $10.65, for a total value of $53,250.00.

Lexeo Therapeutics Price Performance

LXEO stock opened at $7.64 on Thursday. The stock has a market cap of $252.58 million and a price-to-earnings ratio of -0.52. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.38 and a quick ratio of 9.38. The company has a 50 day simple moving average of $9.24 and a 200 day simple moving average of $12.33. Lexeo Therapeutics, Inc. has a 1 year low of $7.47 and a 1 year high of $22.33.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Monday, August 12th. The company reported ($0.64) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.64). Research analysts anticipate that Lexeo Therapeutics, Inc. will post -2.76 EPS for the current fiscal year.

Institutional Investors Weigh In On Lexeo Therapeutics

Hedge funds have recently modified their holdings of the company. RA Capital Management L.P. acquired a new position in Lexeo Therapeutics in the 1st quarter worth about $10,364,000. Janus Henderson Group PLC increased its stake in shares of Lexeo Therapeutics by 9.0% in the first quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company’s stock valued at $39,802,000 after buying an additional 210,047 shares during the period. Artal Group S.A. increased its stake in shares of Lexeo Therapeutics by 32.9% in the first quarter. Artal Group S.A. now owns 801,716 shares of the company’s stock valued at $12,571,000 after buying an additional 198,281 shares during the period. Vanguard Group Inc. raised its holdings in Lexeo Therapeutics by 15.8% in the 1st quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock valued at $7,554,000 after buying an additional 65,573 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Lexeo Therapeutics by 107.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock worth $577,000 after buying an additional 33,013 shares during the period. Institutional investors and hedge funds own 60.67% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on LXEO shares. HC Wainwright boosted their price target on Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, August 13th. Chardan Capital increased their price target on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Leerink Partners lowered their price objective on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Lexeo Therapeutics has an average rating of “Buy” and an average price target of $22.71.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.